Our mission is to transform healthcare by pushing boundaries in developing meaningful genetic medicines for diseases, regardless of prevalence. By taking aim at the underlying genetic cause of the devastating diseases we target, Lexeo seeks to create substantial positive impact and reduce the overwhelming burdens placed on people receiving treatment, their caregivers, and healthcare systems.
At-a-Glance
Lexeo currently has three programs in clinical trials with multiple data readouts expected in 2024.
Lead programs include Phase 1/2 trials of LX2006 for the treatment of Friedreich's ataxia (FA) cardiomyopathy, LX1001 for the treatment of APOE4-associated Alzheimer’s disease and LX2021 for the treatment of arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene (PKP2-ACM).
Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research.
